🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Tarsons Products Limited TARSONS NSEPHARMA

Healthcare · Medical Instruments & Supplies · India
https://www.tarsons.com
Company Profile ↓
₹309.00
-19.57% 1Y
Mkt Cap₹1,644.07 Cr
P/E55.18
P/B2.63
52W High₹386.45
52W Low₹166.46
Book Value₹119.29
EPS (TTM)₹5.60

Company Overview

Tarsons Products Limited manufactures and trades in scientific plastic labware products in India and internationally. The company offers bottles and carboys; boxes and racks; cell cell culture ware, centrifuge ware, clamps and stands, cryoware, desiccator, tubings and connectors, filtration, genomics and PCR consumables, laboratory equipment and utilities, liquid handling consumables and reusables, magnetic stirrer bar, pp storage plates, sampling aids, vials and tubes, and volumetric reusables. It also provides general lab ware products. Its products are used in molecular biology, cell culture, genomics, proteomics, and immunology. Tarsons Products Limited was incorporated in 1983 and is headquartered in Kolkata, India.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 14.5% CAGR over the past five years.

Recent Developments

  • Mar 2026 Revenue of ₹422.51 Cr (+7.7% YoY); net profit ₹14.32 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +7.7%, earnings -51.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR 14.5%, profit CAGR -43.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:14.51%
1 Year:7.67%

Compounded Profit Growth

5 Years:-43.81%
1 Year:-51.89%

Stock Price Performance

1 Year:-19.57%
6 Months:+40.78%
3 Months:+44.85%
1 Month:+49.47%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 65% of range
₹166.46 ₹386.45
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • Golden Cross5d ago
  • RSI (14)71.15 · Overbought
Price Performance
1M+49.47%
3M+44.85%
6M+40.78%
1Y-19.57%
Valuation vs Sector

P/E of 55.18 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 14.5% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 55.2.
  • Earnings shrank at -43.8% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
55.18
Industry PE
39.97
Forward P/E
23.77
PEG Ratio
-
Book Value
₹119.29
Price to Book
2.63
P/S
3.98
EV/EBITDA
17.30
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
14.51%
Profit 5Y
-43.81%
Revenue (YoY)
7.67%
Earnings (YoY)
-51.89%

Profitability & Returns

ROCE
4.82%
ROE
2.26%
ROA
1.21%
Profit Margin
3.39%
Op Margin
5.07%
Gross Margin
67.13%
EPS (Latest Qtr)
₹0.79
EPS (TTM)
₹5.60

Balance Sheet & Liquidity

Debt/Equity
0.62
Quick Ratio
0.51
Current Ratio
1.01
Debt
₹392.96 Cr
Total Assets
₹1,185.82 Cr
Current Assets
₹265.75 Cr
Working Capital
₹1.56 Cr

Ownership

Promoter Holding
73.87%
Chg in Prom Hold
26.57%
FII / Inst Holding
0.95%
Chg in FII Hold
-1.12%

Financial Snapshot

Enterprise Value
₹1,644.07 Cr
Total Revenue (TTM)
₹422.51 Cr
EBITDA
₹140.97 Cr
Free Cash Flow
₹-7.10 Cr
Operating Cash Flow
₹118.48 Cr
Shares Outstanding
₹5.32 Cr
Gross Margin
67.13%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 TARSONS Tarsons Products Limited NSEPHARMA 309.00 55.18 ₹1,644.07 Cr 0.00% 4.82% 2.26% 14.51% -43.81%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Sep 2021Dec 2021Mar 2022Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 76.05 Cr70.66 Cr84.94 Cr61.79 Cr105.72 Cr84.80 Cr99.25 Cr-112.69 Cr91.36 Cr102.33 Cr107.89 Cr120.93 Cr
Cost of Revenue --------37.89 Cr29.30 Cr33.24 Cr35.15 Cr41.18 Cr
Gross Profit --------74.80 Cr62.06 Cr69.09 Cr72.75 Cr79.75 Cr
Operating Expenses 37.58 Cr37.52 Cr40.61 Cr38.91 Cr75.48 Cr66.04 Cr73.94 Cr-57.80 Cr57.29 Cr64.13 Cr66.27 Cr74.56 Cr
Operating Income 33.66 Cr27.79 Cr37.09 Cr12.82 Cr17.91 Cr7.73 Cr11.28 Cr-17.00 Cr4.77 Cr4.96 Cr6.48 Cr5.19 Cr
EBITDA 38.47 Cr33.14 Cr44.33 Cr22.88 Cr30.24 Cr18.76 Cr25.31 Cr-40.80 Cr28.04 Cr33.25 Cr38.59 Cr41.10 Cr
Interest Expense 1.56 Cr1.37 Cr45.00 L2.51 Cr4.25 Cr4.32 Cr4.84 Cr-5.20 Cr5.07 Cr5.17 Cr6.05 Cr6.25 Cr
Pretax Income 33.55 Cr28.88 Cr39.22 Cr13.55 Cr17.04 Cr6.32 Cr14.87 Cr-15.57 Cr3.03 Cr5.59 Cr7.51 Cr5.77 Cr
Tax Provision 8.65 Cr7.41 Cr9.76 Cr3.62 Cr6.73 Cr2.30 Cr4.58 Cr-5.37 Cr1.25 Cr2.27 Cr2.47 Cr1.59 Cr
Net Income 24.90 Cr21.47 Cr29.46 Cr9.93 Cr10.32 Cr4.02 Cr10.29 Cr-10.20 Cr1.78 Cr3.32 Cr5.04 Cr4.18 Cr
Diluted EPS 4.894.045.541.871.940.761.93-1.920.340.620.950.79

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 229.00 Cr-281.36 Cr294.74 Cr392.41 Cr422.51 Cr
Cost of Revenue --78.24 Cr94.29 Cr129.44 Cr138.87 Cr
Gross Profit --203.12 Cr200.45 Cr262.97 Cr283.64 Cr
Operating Expenses 125.00 Cr-98.63 Cr137.25 Cr214.74 Cr262.24 Cr
Operating Income 89.00 Cr-104.49 Cr63.20 Cr48.23 Cr21.40 Cr
EBITDA 103.00 Cr-141.62 Cr111.19 Cr126.69 Cr140.97 Cr
Interest Expense 3.00 Cr-4.39 Cr10.02 Cr19.39 Cr22.55 Cr
Pretax Income 92.00 Cr-108.72 Cr60.77 Cr44.80 Cr21.90 Cr
Tax Provision 23.00 Cr-28.01 Cr18.13 Cr15.03 Cr7.58 Cr
Net Income 69.00 Cr-80.71 Cr42.64 Cr29.77 Cr14.32 Cr
Diluted EPS 3,583.2519.4615.178.015.60-

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 296.00 Cr-725.68 Cr972.18 Cr1,080.04 Cr1,185.82 Cr
Current Assets --252.03 Cr235.28 Cr242.58 Cr265.75 Cr
Cash & Equivalents --59.06 Cr17.11 Cr25.13 Cr23.19 Cr
Inventory --114.37 Cr128.73 Cr126.05 Cr129.78 Cr
Receivables --65.80 Cr77.89 Cr79.62 Cr85.39 Cr
Total Liabilities --156.38 Cr359.32 Cr449.83 Cr551.23 Cr
Current Liabilities --62.91 Cr213.16 Cr175.73 Cr264.19 Cr
Long Term Debt --80.69 Cr102.01 Cr204.87 Cr209.53 Cr
Total Debt 34.00 Cr-110.69 Cr269.02 Cr339.17 Cr392.96 Cr
Total Equity 244.19 Cr-569.30 Cr612.86 Cr630.21 Cr634.69 Cr
Shares Outstanding --5.32 Cr5.32 Cr5.32 Cr5.32 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 68.00 Cr-75.60 Cr102.70 Cr114.24 Cr118.48 Cr
Investing Cash Flow -64.00 Cr--178.55 Cr-284.96 Cr-145.49 Cr-130.37 Cr
Financing Cash Flow -27.00 Cr-84.56 Cr135.62 Cr38.95 Cr8.93 Cr
Capital Expenditure -62.00 Cr--189.97 Cr-184.33 Cr-151.71 Cr-125.58 Cr
Free Cash Flow 6.00 Cr--114.37 Cr-81.63 Cr-37.47 Cr-7.10 Cr
Net Change in Cash -23.00 Cr--18.39 Cr-46.63 Cr7.70 Cr-2.96 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --72.2%68.0%67.0%67.1%
Operating Margin % 38.9%-37.1%21.4%12.3%5.1%
Net Margin % 30.1%-28.7%14.5%7.6%3.4%
ROE % 28.3%-14.2%7.0%4.7%2.3%
ROCE % --15.8%8.3%5.3%2.3%

Shareholding Pattern

Insiders
73.87%
Institutions
0.95%
Public Float
3.66%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TARSONS

Google News Fri, 14 Nov 2025

Tarsons Products Limited's (NSE:TARSONS) P/E Still Appears To Be Reasonable - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxOY1Myb1ZGQWs5WHdTQ3FBenBiUThrX3B0WklQSHNhejJUSmdORDVKcU8wR0UxVzhFNTY3cjY4V296bHZtM2NrczQ4WWlWeGEtOG1ZWWFKUTdQLS1XdnBfOXM1S0gzSGtFYzR3U0hvNUVGNC1feV9fYm94Ull1V0VqbVpJd2RaV0NzZkdrNn…

Google News hu, 18 Jun 2026

Tarsons Products delivers 67% return after Fair Value signal By Investing.com - Investing.com India

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOSmhvQks0R3NoLW1vWXhfQTk3S0p6dEZwZGlpLUVTRG1xTXpERmdpa0pOQXJMaUpjaDJqZTZmS3hzanFGUHdFdmRMSHNnU0cySXFqdEVfdnV3WTNvOVZCRU5hQ1lWMmpJbDFWb1BPSGNfOHNOZ0VKc3gxdHFmMnFJYWlpYmFWMHl4UTVubz…

Google News hu, 12 Mar 2026

Tarsons Products - Spooked by Iran war? 7 stocks that are predicted to double investor wealth over next 12 months - The Economic Times

<a href="https://news.google.com/rss/articles/CBMijwJBVV95cUxPX0d5MnhKNUlicVJLV3o4T1VXSTJITFkxdmtDdUpoTWlSbXBVY2d3aTk4SzV4LW4yV2ZlSFduNmZZU2V6TGRldmxnQW5pTFJsOVZoN1lzek5LTktvVmxvbXhYSVhQMEt4TlNZMDgwcVRnUkZoQ3NSdV9xYXh6ZWphbWpMeTI3WDBPSjJIRW…

Google News Mon, 08 Jun 2026

Tarsons Products to attend investor conference on June 11, 2026 - scanx.trade

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxNWFY3bS1KUGlUYXJJUUl6Wmw3WTZMeFl1VEoxdE1pTm0wMU9YdEpGNFg0OE0teHZ3NTl2RzhwbDFjZllyakJzQWwwUXUxYVVyaWhFSHo1aU4yN2FJTGRmR1E2ZjJDWm16Y05JMGcteGRia2VuTDJMVGpVRHowYTdoNWJXdmM0dDF0dWVWU2…

Google News Sat, 21 Mar 2026

Tech Query: Infosys, Reliance Industries (RIL), Indian Energy Exchange (IEX), Tata Consultancy Services (TCS), Tarsons Products - What Is The Outlook? Where Are These Stocks Headed? - BusinessLine

<a href="https://news.google.com/rss/articles/CBMi7wJBVV95cUxNVmdHU3pZbkZsMUtTUHJhMDFpbllJb2g0MElWTWY3QlBqeS1EZHZlTEtHdTVJTV93S0sxdzNvOHlIamFzR051aEpSWjNNSU5pcks5enROZGlrWkZTTlpuOXpCUmY0cmlkSWp1QWktbmIxT3ZvaVBoMWYwTE81WTRnZEFpTkxILVhDSHhmWT…

Google News ue, 25 Nov 2025

This smallcap plastic labware producer has declined over 30% during a 14-day losing streak - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPMjVERWxtYWF5VWRReXdUNTZxbGttd1liZUd4ZnU1MXE5Z0FoNV8tSmFGZHotNlNSZ29Eam42YjM0SVI3dngwY051NmdCTkNWOXdTcXZ5bWE5dVptLWxRU0kxQWJ4RGFMWUYwZElYUDk4N3BsMmU0MWJLNkxiZDJOd3B6QUtTMkFIbFN4bF…

TARSONS — Frequently Asked Questions

What is the current share price of Tarsons Products Limited (TARSONS)?

As of 2026-07-15 09:52 IST, Tarsons Products Limited (TARSONS) trades at ₹309.00 on NSE. Its 52-week range is ₹166.46 to ₹386.45.

What is the market capitalisation of TARSONS?

Tarsons Products Limited (TARSONS) has a market capitalisation of ₹1,644.07 Cr on NSE.

What is the P/E ratio of TARSONS?

TARSONS trades at a trailing price-to-earnings (P/E) ratio of 55.18. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 2.63.

What is the return on equity (ROE) of TARSONS?

TARSONS has a return on equity (ROE) of 2.26%. Its return on capital employed (ROCE) is 4.82%.

Is TARSONS a good stock to buy?

This page provides a data-driven analysis of Tarsons Products Limited (TARSONS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space